EA029678B9 - Четвертичные соли пиперидиния - Google Patents
Четвертичные соли пиперидинияInfo
- Publication number
- EA029678B9 EA029678B9 EA201500209A EA201500209A EA029678B9 EA 029678 B9 EA029678 B9 EA 029678B9 EA 201500209 A EA201500209 A EA 201500209A EA 201500209 A EA201500209 A EA 201500209A EA 029678 B9 EA029678 B9 EA 029678B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- piperidinium
- quaternary salts
- oabs
- copd
- acetoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к фармацевтическим композициям, содержащим галид 1-алкил-1-метил-4-[(2,2-дифенил-2-пропокси)ацетокси]пиперидиния, описываемый формулой I, в качестве активного ингредиента, и их применению для лечения синдрома гиперактивного мочевого пузыря (OABS), хронических обструктивных заболеваний легких (COPD) или астмы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261681415P | 2012-08-09 | 2012-08-09 | |
PCT/US2013/052626 WO2014025569A1 (en) | 2012-08-09 | 2013-07-30 | Piperidinium quaternary salts |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201500209A1 EA201500209A1 (ru) | 2015-05-29 |
EA029678B1 EA029678B1 (ru) | 2018-04-30 |
EA029678B9 true EA029678B9 (ru) | 2018-07-31 |
Family
ID=50068488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201500209A EA029678B9 (ru) | 2012-08-09 | 2013-07-30 | Четвертичные соли пиперидиния |
Country Status (14)
Country | Link |
---|---|
US (1) | US9896416B2 (ru) |
EP (1) | EP2882711B1 (ru) |
JP (1) | JP6345665B2 (ru) |
KR (2) | KR102240999B1 (ru) |
CN (2) | CN104603108A (ru) |
AU (1) | AU2013300009B2 (ru) |
BR (1) | BR112015002832B1 (ru) |
CA (1) | CA2881182C (ru) |
EA (1) | EA029678B9 (ru) |
HK (1) | HK1211572A1 (ru) |
IL (1) | IL236996A0 (ru) |
IN (1) | IN2015DN01018A (ru) |
MX (1) | MX356386B (ru) |
WO (1) | WO2014025569A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3265128A4 (en) | 2015-03-06 | 2018-09-12 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system muscarinic agonist combination |
WO2017015349A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
EP4354912A3 (en) | 2019-08-22 | 2024-04-24 | Ofinno, LLC | Policy control for multiple accesses |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD106643A1 (ru) | 1973-07-12 | 1974-06-20 | ||
CN1285348A (zh) | 1999-08-20 | 2001-02-28 | 广东康美药业股份有限公司 | 盐酸丙哌维林合成工艺 |
DE10129832A1 (de) * | 2001-06-17 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
CA2384922C (en) * | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
KR100500760B1 (ko) | 2003-07-22 | 2005-07-14 | 동방에프티엘 주식회사 | 염산 프로피베린의 제조방법 |
KR100510788B1 (ko) | 2003-07-22 | 2005-08-26 | 동방에프티엘 주식회사 | 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법 |
SI1713473T1 (sl) * | 2004-02-06 | 2013-06-28 | Meda Pharma Gmbh & Co. Kg | Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB |
US8548786B2 (en) * | 2005-08-12 | 2013-10-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neuronal avalanche assay |
CN1951938A (zh) * | 2005-10-21 | 2007-04-25 | 刘丽娅 | 戊乙奎醚季铵盐及其衍生物 |
SE0600876L (sv) | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
CN101490003A (zh) * | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
WO2007123465A1 (en) | 2006-04-24 | 2007-11-01 | Astrazeneca Ab | New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder |
JP2012530050A (ja) * | 2010-03-15 | 2012-11-29 | ラマクリシュナ、ラメシャ アンダガル | 塩酸プロピベリンの合成 |
KR101149821B1 (ko) | 2010-04-05 | 2012-05-24 | 하나제약 주식회사 | 디페닐아세테이트 유도체의 새로운 제조방법 |
CN102218063B (zh) | 2011-04-12 | 2013-03-13 | 贵州神奇制药有限公司 | 盐酸丙哌维林药物的制备方法和产品及其检测方法 |
EA038489B1 (ru) * | 2012-09-05 | 2021-09-06 | Чейс Фамасьютикалз Корпорейшн | Антихолинэргическая нейропротективная композиция и способы |
-
2013
- 2013-07-30 AU AU2013300009A patent/AU2013300009B2/en not_active Ceased
- 2013-07-30 IN IN1018DEN2015 patent/IN2015DN01018A/en unknown
- 2013-07-30 CN CN201380042085.3A patent/CN104603108A/zh active Pending
- 2013-07-30 CN CN201810664740.3A patent/CN108658842A/zh active Pending
- 2013-07-30 EP EP13827594.6A patent/EP2882711B1/en active Active
- 2013-07-30 BR BR112015002832-2A patent/BR112015002832B1/pt not_active IP Right Cessation
- 2013-07-30 CA CA2881182A patent/CA2881182C/en active Active
- 2013-07-30 MX MX2015001769A patent/MX356386B/es active IP Right Grant
- 2013-07-30 EA EA201500209A patent/EA029678B9/ru unknown
- 2013-07-30 WO PCT/US2013/052626 patent/WO2014025569A1/en active Application Filing
- 2013-07-30 KR KR1020207005139A patent/KR102240999B1/ko active IP Right Grant
- 2013-07-30 KR KR20157006047A patent/KR20150040355A/ko not_active Application Discontinuation
- 2013-07-30 JP JP2015526567A patent/JP6345665B2/ja active Active
- 2013-07-30 US US14/419,381 patent/US9896416B2/en active Active
-
2015
- 2015-01-29 IL IL236996A patent/IL236996A0/en unknown
- 2015-12-10 HK HK15112219.3A patent/HK1211572A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014025569A1 (en) | 2014-02-13 |
US20150203452A1 (en) | 2015-07-23 |
HK1211572A1 (en) | 2016-05-27 |
IN2015DN01018A (ru) | 2015-06-26 |
CN104603108A (zh) | 2015-05-06 |
EP2882711B1 (en) | 2017-10-25 |
BR112015002832A2 (ru) | 2017-07-04 |
US9896416B2 (en) | 2018-02-20 |
CA2881182A1 (en) | 2014-02-13 |
KR20150040355A (ko) | 2015-04-14 |
JP6345665B2 (ja) | 2018-06-20 |
AU2013300009A1 (en) | 2015-02-26 |
EP2882711A4 (en) | 2016-02-10 |
MX2015001769A (es) | 2015-05-08 |
EA029678B1 (ru) | 2018-04-30 |
EP2882711A1 (en) | 2015-06-17 |
BR112015002832B1 (pt) | 2022-08-16 |
CN108658842A (zh) | 2018-10-16 |
KR102240999B1 (ko) | 2021-04-15 |
EA201500209A1 (ru) | 2015-05-29 |
KR20200022522A (ko) | 2020-03-03 |
IL236996A0 (en) | 2015-03-31 |
JP2015524469A (ja) | 2015-08-24 |
MX356386B (es) | 2018-05-28 |
CA2881182C (en) | 2021-01-26 |
AU2013300009B2 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501439A1 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
IN2014DN09434A (ru) | ||
MX2016002794A (es) | Compuestos antiproliferativos. | |
WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
EA201591957A1 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
EA201791780A1 (ru) | Ингаляционный раствор тиотропия для небулайзерного распыления | |
PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
MX350793B (es) | Pirroldicarboxamidas condensadas y su uso como agentes farmaceuticos. | |
PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
EA029678B9 (ru) | Четвертичные соли пиперидиния | |
EP3037093A4 (en) | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases | |
MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
WO2013188279A8 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
WO2013175347A3 (en) | Compositions and methods for treatment of respiratory disorders | |
NZ724063A (en) | Pyrazine derivatives having pharmaceutical activity | |
IN2013DE00880A (ru) | ||
IN2013MU01152A (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent |